Transposon Therapeutics, Inc.
Transposon Therapeutics, Inc. is developing TPN-101 (also known as Censavudine) and other LINE-1 reverse transcriptase inhibitors for the treatment of rare neurodegenerative diseases such as progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD).
Funding history
About Transposon Therapeutics, Inc.
How much funding has Transposon Therapeutics, Inc. raised?
Transposon Therapeutics, Inc. has raised $4.7M in total funding. The most recent round was Series A.
Where is Transposon Therapeutics, Inc. headquartered?
Transposon Therapeutics, Inc. is headquartered in San Diego, CA.
What does Transposon Therapeutics, Inc. do?
Transposon Therapeutics, Inc. is developing TPN-101 (also known as Censavudine) and other LINE-1 reverse transcriptase inhibitors for the treatment of rare neurodegenerative diseases such as progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD).
What problem does Transposon Therapeutics, Inc. solve?
Neurodegenerative and aging-related diseases currently lack transformational treatments.
What's Transposon Therapeutics, Inc.'s solution?
Transposon Therapeutics is developing therapies for these conditions, with a pipeline that includes TPN-101 targeted at PSP, ALS/FTD, and AD, along with novel NRTIs and PKR-related programs.
What makes Transposon Therapeutics, Inc. notable?
Developing Alzheimer's drug candidate TPN-101, the company received a direct investment from the Alzheimer's Drug Discovery Foundation to advance the therapy.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.